Available to passage freely in academic laboratory*
Receive 5 NSG™ mice at no additional cost for
each PDX Live™ model purchased.**
Highly characterized, clinically relevant models.
|Primary Site||Model ID||AKA|
Additional live models may be available, and are subject to change.
For specific model availability, please contact:
Technical Information Services
1-800-422-6423 (US, Canada & Puerto Rico)
1-207-288-5845 (from any location)
JAX Technical Support
|Study Type||Arms||Vehicle||SOC||Drug A||Drug B||Combination
|1. Pilot efficacy study||3||1||1||1||0||0|
|2. Dose response||5||1||1||3||0||0|
|3. Drug combination||4||1||0||1||1||1|
We provide you data in weeks with study-ready clinically relevant patient-derived xenografts in the most robust mouse models.
Contact Technical Support
Figure 1. Mice bearing passage 3 colon adenocarcinoma PDX tumor (TM00170) were treated with vehicle control: D5W (dark grey), 20mg/ kg 5-Fu (light blue), 10mg/kg Oxaliplatin (orange) and 5-Fu + Oxaliplatin (dark blue) once per week for 3 weeks. Vehicle and 5-Fu were administrated intravenously and Oxaliplatin was dosed intraperitoneally. The readout for compound efficacy–alone or in combination-was assessed by taking tumor caliper measurements and body weight twice weekly. Ten NSG™ mice were used per arm.
Figure 2. Mice bearing passage 4 TM00089 PDX tumor were treated with vehicle control (D5W), Cisplatin (2mg/kg), Cyclophosphamide (40mg/kg) and Doxorubicin (2mg/kg) intravenously, once per week for 3 weeks; Docetaxel (15mg/kg) was dosed once per week only for 2 weeks intravenously.
Figure 3. A) Patient tumor for PDX model TM00089 (aka, BR0620); PR marker (negative). B) P0 tumor #037 for PDX model TM00089 (aka, BR0620F); estradiol supplemented; PR marker. C) P1 tumor for PDX model TM00089 (aka, BR0620F); estradiol supplemented; PR marker (negative)
Figure 4. Mice bearing TM00199 PDX samples at passage 3 were used to create five treatment groups of twelve mice each: vehicle control (0.5 % carboxymethylcellulose); erlotinib (50 mg/kg); afatinib (20 mg/kg); cetuximab (10 mg/kg); and afatinib plus cetuximab (20 mg/kg and 10 mg/kg, respectively). Vehicle, erlotinib, and afatinib were IP dosed daily for 21 days. Cetuximab was dosed intravenously three times weekly, for three weeks. Mice were monitored for tumor volume.
Figure 5. A) P1 tumor #940_001 for PDX model TM00199 (aka, LG0703F). B) P1 tumor #940_006 for PDX model TM00199 (aka, LG0703F).